Join to View Full Profile
1600 Eureka RdRoseville, CA 95661
Phone+1 916-784-5626
Dr. Adada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mohamad Adada is an Oncologist based in Rochester, MN specializing in Internal Medicine. He graduated from the Stony Brook University Health Sciences Center School of Medicine in 2017 and completed his residency at the Mayo Clinic College of Medicine and Science in Rochester from 2017-2020. Dr. Adada has an impressive record of publications with topics ranging from the therapeutic use of CART19 cell therapy to the regulation of Programmed Cell Death, each being cited by other publications multiple times. His work has been featured in esteemed journals such as Blood, Cancer Immunology Research, and The Journal of Biological Chemistry.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2017 - 2020
Stony Brook University Health Sciences Center School of MedicineClass of 2017
Certifications & Licensure
CA State Medical License 2023 - 2027
MN State Medical License 2018 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 8 citationsCD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.R Leo Sakemura, Claudia Manriquez Roman, Paulina Horvei, Elizabeth L Siegler, James H Girsch
Blood. 2024-01-18 - 4 citationsAXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.R Leo Sakemura, Mehrdad Hefazi, Michelle J Cox, Elizabeth L Siegler, Sutapa Sinha
Cancer Immunology Research. 2023-09-01 - 2 citationsAssessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model.Claudia Manriquez Roman, R Leo Sakemura, Brooke L Kimball, Fang Jin, Roman H Khadka
Journal of Visualized Experiments. 2023-02-10
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
